Loading stock data…
ARCT
$8.63-0.58 (-6.34%)
Market ClosedLast close May 11
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $8.63. The stock is currently near its 52-week low of $5.85, remaining 20.3% below its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why ARCT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.63
Potential Upside
5%
Whystock Fair Value$9.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$23.20+168.7%
Range$8.00 – $68.00
Fundamentals
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$247.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.74%
Volume
Today's trading volume
498,404
Recent News
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcturus Therapeutics Holdings Inc.'s Q1 2026 earnings call
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics Q1 Earnings Call Highlights
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call, while also discussing ongoing partner activity for its self-amplifying mRNA COVID-19 vaccine in Jap
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed investor has been buying stocks trading well below their all-time highs.